(-0.07%) 5 465.22 points
(-0.07%) 39 087 points
(0.18%) 17 749 points
(-0.58%) $80.36
(-4.32%) $2.64
(-0.85%) $2 311.00
(-0.05%) $28.86
(2.30%) $1 009.10
(0.30%) $0.936
(0.72%) $10.68
(0.50%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases...
Stats | |
---|---|
Today's Volume | 8.56M |
Average Volume | 0 |
Market Cap | 0.00 |
EPS | $-0.340 ( Q2 | 2022-08-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0300 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0750 (106.99%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-19 | Van Den Broek Richard | Buy | 3 750 | Common Stock |
2023-05-19 | Van Den Broek Richard | Sell | 3 750 | Restricted Stock Units |
2023-05-19 | Thorp Clay | Buy | 3 750 | Common Stock |
2023-05-19 | Thorp Clay | Buy | 3 750 | Restricted Stock Units |
2023-05-19 | Humphries William D. | Buy | 2 538 | Common Stock |
INSIDER POWER |
---|
-91.57 |
Last 98 transactions |
Buy: 2 306 852 | Sell: 1 915 751 |
Volume Correlation
PhaseBio Pharmaceuticals, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PhaseBio Pharmaceuticals, Correlation - Currency/Commodity
PhaseBio Pharmaceuticals, Financials
Annual | 2021 |
Revenue: | $10 831.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2021 |
Revenue: | $10 831.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2020 |
Revenue: | $320 000 |
Gross Profit: | $320.00 (0.10 %) |
EPS: | $-3.39 |
FY | 2019 |
Revenue: | $2.36M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.430 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PhaseBio Pharmaceuticals,
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators